CRISPR-Based Diagnostics (Cas12 & Cas13): A Master Guide for Veterinary Clinical Pathology

Introduction

CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)-based diagnostics represent a revolutionary class of nucleic acid detection platforms that leverage the collateral cleavage activity of Cas12 and Cas13 enzymes. Unlike traditional gene editing applications, these systems are engineered for rapid, sensitive, and specific detection of DNA or RNA targets without the need for complex thermocycling. In veterinary medicine, CRISPR diagnostics offer a transformative potential for point-of-care detection of infectious diseases, antimicrobial resistance markers, and even inherited genetic disorders. This guide provides a comprehensive, textbook-level overview of the principles, protocols, performance characteristics, and applications of Cas12- and Cas13-based diagnostics in veterinary clinical pathology and virology.

Historical Context

The CRISPR-Cas system was first identified in 1987 as a bacterial adaptive immune mechanism. The breakthrough came with the characterization of Cas9 as a programmable endonuclease in 2012, ushering the CRISPR revolution in genome editing. However, the diagnostic potential of CRISPR remained largely unexplored until 2017-2018, when two seminal studies demonstrated that Cas13 (SHERLOCK) and Cas12 (DETECTR) could be repurposed for nucleic acid detection.

Jennifer Doudna's group reported that Cas12a (Cpf1) exhibits nonspecific single-stranded DNase activity upon target recognition (Chen et al., 2018). This collateral cleavage can be harnessed to cleave fluorescent reporter molecules, enabling detection of human papillomavirus. Simultaneously, Feng Zhang's team introduced SHERLOCK (Specific High-sensitivity Enzymatic Reporter UnLOCKing) using Cas13a, which shows collateral RNase activity after binding its RNA target (Gootenberg et al., 2017). Subsequent iterations-SHERLOCKv2, HUDSON (Heating Unextracted Diagnostic Samples to Obliterate Nucleases)-improved sensitivity, multiplexing, and sample preparation. These developments have made CRISPR-Dx a viable alternative to PCR in field and laboratory settings.

Chemical and Physical Principles

Cas12 (Cpf1) System

Cas12 is a class 2, type V CRISPR nuclease that recognizes double-stranded DNA (dsDNA) targets containing a short protospacer adjacent motif (PAM; typically 5'-TTTV-3' for Cas12a). The guide RNA (crRNA) directs Cas12 to the complementary target sequence. Upon specific recognition and R-loop formation, the nuclease domain (RuvC) cleaves the target dsDNA. Critically, this activation triggers a nonspecific trans-cleavage activity that degrades any single-stranded DNA (ssDNA) in the vicinity. For diagnostics, a fluorophore-quencher ssDNA reporter is included; cleavage releases the fluorophore, generating a measurable fluorescent signal.

Cas13 (C2c2) System

Cas13 belongs to class 2, type VI CRISPR systems and specifically targets single-stranded RNA (ssRNA). No PAM is required; instead, a protospacer flanking sequence (PFS) is needed. Upon guide RNA binding to target ssRNA, Cas13 undergoes a conformational change that activates its two HEPN (Higher Eukaryotes and Prokaryotes Nucleotide-binding) domains. This activation leads to collateral, sequence-independent cleavage of any ssRNA molecule nearby. For detection, an RNA reporter with fluorophore and quencher is included. Cas13's RNA-specific targeting makes it ideal for detecting RNA viruses (e.g., influenza, coronavirus) and for RNA-based transcriptomic applications.

Mechanism of CRISPR-Based Detection

The core detection cascade consists of three steps:

1. Target Recognition: A custom-designed CRISPR RNA (crRNA) guides the Cas12 or Cas13 enzyme to the complementary nucleic acid sequence in the sample.
2. Enzyme Activation: Upon perfect base pairing (and PAM/PFS recognition for Cas12), the enzyme's catalytic site becomes allosterically activated. This activation is highly specific; even single-nucleotide mismatches can abolish collateral cleavage, providing single-base resolution.
3. Collateral Cleavage and Signal Generation: The activated enzyme nonspecifically cleaves nearby reporter molecules. In fluorescence-based readouts, cleavage separates a fluorophore from its quencher, increasing fluorescence. In lateral flow formats, the reporter is typically a biotin-fluorescein ssDNA that, when intact, is captured on a test line. Cleavage products are detected at a separate control line.

Because collateral cleavage is catalytic-a single activated enzyme cleaves thousands of reporter molecules-the signal is amplified without thermal cycling. However, to achieve attomolar sensitivity, a preceding isothermal amplification step (e.g., RPA, LAMP) is usually employed. Combining amplification with CRISPR detection yields sensitivities comparable to qPCR (1-10 copies/μL) in under one hour.

Laboratory Protocols and Quality Assurance

General Protocol Workflow

1. Sample Preparation: Nucleic acids are extracted using standard kits (e.g., spin columns, magnetic beads) or via rapid lysis methods. HUDSON (for Cas13) uses heat and chemical reduction to inactivate nucleases and release RNA directly from clinical samples without extraction.
2. Isothermal Amplification (optional but recommended): Target regions are amplified using Recombinase Polymerase Amplification (RPA) or Loop-mediated Isothermal Amplification (LAMP). RPA operates at 37-42°C, LAMP at 60-65°C. Primers are designed to amplify the region complementary to the crRNA.
3. CRISPR Detection Reaction: The amplified product is mixed with Cas12 or Cas13 enzyme, crRNA, and reporter substrate in a reaction buffer (typically containing Tris, MgCl₂, NaCl, and a reducing agent). For Cas13, an RNase inhibitor is added. The reaction is incubated at 37°C (Cas12) or 37°C (Cas13) for 10-60 minutes.
4. Readout: Fluorescence is measured in a real-time PCR instrument, a plate reader, or using a handheld fluorometer. For lateral flow detection, the reaction mixture is applied to a lateral flow strip, and the result is read visually within 2-5 minutes.

Controls and Quality Assurance

• Positive Control: In vitro transcribed or synthetic target nucleic acid of known concentration.
• Negative Control: Nuclease-free water or a non-target sequence (e.g., unrelated pathogen genome).
• Internal Control: A host gene (e.g., canine RNase P, beta-actin) is co-amplified with a separate crRNA to confirm sample adequacy and extraction efficiency.
• No-Amplification Control: To verify that the CRISPR reaction itself does not generate false positives due to crRNA-independent cleavage.
• Replicates: Triplicate reactions are recommended for quantitative applications. Validated limits of detection (LOD) should be determined using serial dilutions in a representative matrix (e.g., serum, nasal swab, feces).

Quality assurance includes regular monitoring of enzyme activity using standardized reporter substrates, verifying crRNA integrity, and implementing a contamination control protocol (separate areas for pre- and post-amplification, use of dUTP/UNG for carryover prevention).

Comparative Analysis: Sensitivity, Specificity, and Cost

Key Takeaway: CRISPR-Dx bridges the gap between high-sensitivity laboratory methods (qPCR) and rapid, low-cost point-of-care devices (lateral flow). It offers near-PCR sensitivity with isothermal operation, minimal equipment, and extreme specificity. The main limitations are the need for an amplification step in most formats and limited multiplexing capacity.

Applications in Veterinary Medicine

Viral Diseases

CRISPR diagnostics have been successfully applied to a wide range of veterinary viruses. For DNA viruses, Cas12-based DETECTR has been used to detect African swine fever virus (ASFV) directly from whole blood and tissue samples, achieving an LOD of ~10 copies/μL and 100% specificity. Similarly, Canine parvovirus type 2 (CPV-2) can be detected from fecal swabs using Cas12a with RPA, providing results in under one hour that correlate with qPCR.

For RNA viruses, Cas13 is the platform of choice. Foot-and-mouth disease virus (FMDV) detection using SHERLOCK has been validated on vesicular fluid and epithelial suspensions, demonstrating serotype-specific identification (including differentiation from vesicular stomatitis virus). Rabies virus RNA detection from brain tissue has been achieved with a modified SHERLOCK protocol, enabling field-deployable surveillance. Other examples include Influenza A virus (canine, equine, avian), Canine distemper virus, Porcine reproductive and respiratory syndrome virus (PRRSV), and multiple coronaviruses (canine, feline, bovine). In many cases, CRISPR-Dx allows differentiation of closely related strains via single-nucleotide polymorphisms.

Bacterial Diseases

Bacterial detection using CRISPR-Dx typically targets species-specific genomic sequences or antimicrobial resistance (AMR) genes. Leptospira interrogans detection from blood or urine using Cas12a has been reported, with sensitivities <10 genome equivalents per reaction. Brucella abortus and Mycobacterium bovis detection have been demonstrated using Cas12a combined with RPA, offering faster turnaround than culture. For AMR, mecA (methicillin resistance) and blaNDM (carbapenem resistance) in veterinary Staphylococcus and E. coli isolates can be detected with single-base specificity. The ability to differentiate between methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-susceptible strains is particularly valuable in companion animal and livestock settings.

Genetic and Metabolic Diseases

While less developed than infectious disease applications, CRISPR diagnostics can detect inherited genetic mutations. For example, the MDR1 mutation (ABCB1-1Δ) in dogs, which causes ivermectin sensitivity, can be identified by Cas12a using a mutation-specific crRNA that targets the 4-base pair deletion. Similarly, mutations causing progressive retinal atrophy (PRA) in dogs and Chediak-Higashi syndrome in cats have been targeted. Such applications typically require a preceding PCR or isothermal amplification step to enrich the target region. The primary utility in metabolic diseases is for genetic screening and predisposition testing, rather than acute metabolic disorders.

Future Directions

The next generation of CRISPR diagnostics aims to eliminate the amplification step entirely. Amplification-free Cas13 detection (using optimized crRNAs, high enzyme concentrations, or digital droplet CRISPR) has shown promise with sensitivities approaching 10⁴ copies/μL, sufficient for high-titer viremias. Integration with microfluidics and smartphone-based fluorescence readers will enable true point-of-care panels for multiple pathogens. Multiplexed detection using orthogonal Cas enzymes (e.g., Cas12, Cas13, and Cas14) or spatial separation (arrayed microwells) is under development. In the veterinary context, these innovations will support herd-level screening, wildlife disease surveillance, and rapid outbreak response.

References

1. Fenner's Veterinary Virology. 5th ed. Maclachlan NJ, Dubovi EJ, editors. Academic Press; 2017.
2. Greene CE, editor. Infectious Diseases of the Dog and Cat. 4th ed. Saunders; 2012.
3. Sambrook J, Russell DW. Molecular Cloning: A Laboratory Manual. 3rd ed. Cold Spring Harbor Laboratory Press; 2001.
4. Ausubel FM, Brent R, Kingston RE, et al. Current Protocols in Molecular Biology. Wiley; 2003.
5. Gootenberg JS, Abudayyeh OO, Lee JW, et al. Nucleic acid detection with CRISPR-Cas13a/C2c2. Science. 2017;356(6336):438-442.
6. Chen JS, Ma E, Harrington LB, et al. CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity. Science. 2018;360(6387):436-439.
7. Ali Z, Aman R, Mahas A, et al. iSCAN: An RT-LAMP-coupled CRISPR-Cas12 module for rapid, sensitive detection of SARS-CoV-2. Virus Res. 2020;288:198129.
8. Myhrvold C, Freije CA, Gootenberg JS, et al. Field-deployable viral diagnostics using CRISPR-Cas13. Science. 2018;360(6387):444-448.
9. Kellner MJ, Koob JG, Gootenberg JS, et al. SHERLOCK: nucleic acid detection with CRISPR nucleases. Nat Protoc. 2019;14(10):2986-3012.
10. Wang X, Ji P, Fan H, et al. Rapid and sensitive detection of African swine fever virus using CRISPR-Cas12a-based lateral flow assay. Transbound Emerg Dis. 2021;68(4):2140-2148.